Long-term safety of approved biologics for ulcerative colitis

Ulcerative colitis

Ungaro, R. C., Mehandru, S., Allen, P. B., Peyrin‐Biroulet, L., & Colombel, J. (2016) · The Lancet · doi:10.1016/s0140-6736(16)32126-2 · Cited by 3,659 · see citing works

Ulcerative Colitis

Ford Alexander, C., Paul, M., Hanauer Steven, B., 谭蓓, & Dong, W. Z. (2001) · Cited by 3,021 · see citing works

Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis

Feagan, B. G., Rutgeerts, P. J., Sands, B. E., Hanauer, S. B., Colombel, J., Sandborn, W. J., Assche, G. V., Axler, J. L., Kim, H. J., Danese, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215734 · Cited by 2,892 · see citing works

Inflammatory bowel disease

Abraham, C., & Cho, J. H. (2009) · New England Journal of Medicine · doi:10.1056/nejmra0804647 · Cited by 2,712 · see citing works

Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 2: current management

Harbord, M., Eliakim, R., Bettenworth, D., Karmiris, K., Katsanos, K., Kopylov, U., Kucharzik, T., Molnár, T., Raine, T., Sebastian, S., et al. (2017) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjx009 · Cited by 1,180 · see citing works

The safety of vedolizumab for ulcerative colitis and Crohn's disease

Colombel, J., Sands, B. E., Rutgeerts, P. J., Sandborn, W. J., Danese, S., D’Haens, G., Panaccione, R., Loftus, E. V., Sankoh, S., Fox, I. H., et al. (2016) · Gut · doi:10.1136/gutjnl-2015-311079 · Cited by 805 · see citing works

Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis

Sands, B. E., Peyrin‐Biroulet, L., Loftus, E. V., Danese, S., Colombel, J., Törüner, M., Jonaitis, L. V., Abhyankar, B., Chen, J., Rogers, R., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1905725 · Cited by 759 · see citing works

Risk of Serious and Opportunistic Infections Associated With Treatment of Inflammatory Bowel Diseases

Kirchgesner, J., Lemaître, M., Carrat, F., Zureik, M., Carbonnel, F., & Dray‐Spira, R. (2018) · Gastroenterology · doi:10.1053/j.gastro.2018.04.012 · Cited by 610 · see citing works

ACG clinical guideline: Preventive care in inflammatory bowel disease

Farraye, F. A., Melmed, G. Y., Lichtenstein, G. R., & Kane, S. V. (2017) · American Journal of Gastroenterology · doi:10.1038/ajg.2016.537 · Cited by 473 · see citing works

Biologic Therapies and Risk of Infection and Malignancy in Patients With Inflammatory Bowel Disease: A Systematic Review and Network Meta-analysis

Bonovas, S., Fiorino, G., Allocca, M., Lytras, T., Nikolopoulos, G. K., Peyrin‐Biroulet, L., & Danese, S. (2016) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2016.04.039 · Cited by 386 · see citing works

Efficacy and Safety of Vedolizumab Subcutaneous Formulation in a Randomized Trial of Patients With Ulcerative Colitis

Sandborn, W. J., Baert, F., Danese, S., Krznarić, Ž., Kobayashi, T., Yao, X., Chen, J., Rosario, M., Bhatia, S., Kisfalvi, K., et al. (2019) · Gastroenterology · doi:10.1053/j.gastro.2019.08.027 · Cited by 333 · see citing works

Induction and maintenance treatment of inflammatory bowel disease: A comprehensive review

Jeong, D. Y., Kim, S., Son, M. J., Son, C. Y., Kim, J. Y., Kronbichler, A., Lee, K. H., & Shin, J. I. (2019) · Autoimmunity Reviews · doi:10.1016/j.autrev.2019.03.002 · Cited by 215 · see citing works

Long-term Infliximab Maintenance Therapy for Ulcerative Colitis: The ACT-1 and -2 Extension Studies

Reinisch, W., Sandborn, W. J., Rutgeerts, P. J., Feagan, B. G., Rachmilewitz, D., Hanauer, S. B., Lichtenstein, G. R., de Villiers, W. J. S., BLANK, M. A., Lang, Y., et al. (2011) · Inflammatory Bowel Diseases · doi:10.1002/ibd.21697 · Cited by 208 · see citing works

Efficacy and safety of CT‐P13 , a biosimilar of infliximab, in patients with inflammatory bowel disease: A retrospective multicenter study

Jung, Y. S., Park, D. I., Kim, Y. H., Lee, J. H., Seo, P. J., Cheon, J. H., Kang, H. W., & Kim, J. W. (2015) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.12997 · Cited by 175 · see citing works

Infliximab in severe ulcerative colitis: short‐term results of different infusion regimens and long‐term follow‐up

Kohn, A., Daperno, M., Armuzzi, A., Cappello, M., Biancone, L., Orlando, A., Viscido, A., Annese, V., Riegler, G., Meucci, G., et al. (2007) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2007.03415.x · Cited by 169 · see citing works

Four-Year Maintenance Treatment With Adalimumab in Patients with Moderately to Severely Active Ulcerative Colitis: Data from ULTRA 1, 2, and 3

Colombel, J., Sandborn, W. J., Ghosh, S. K., Wolf, D. C., Panaccione, R., Feagan, B. G., Reinisch, W., Robinson, A. M., Lazar, A., Kron, M., et al. (2014) · The American Journal of Gastroenterology · doi:10.1038/ajg.2014.242 · Cited by 166 · see citing works

Current and Emerging Biologics for Ulcerative Colitis

Park, S. C., & Jeen, Y. T. (2014) · Gut and Liver · doi:10.5009/gnl14226 · Cited by 134 · see citing works

Long‐term efficacy and safety of biosimilar infliximab (CT‐P13) after switching from originator infliximab: open‐label extension of the NOR‐SWITCH trial

Goll, G. L., Jørgensen, K. K., Sexton, J., Olsen, I. C., Bolstad, N., Haavardsholm, E. A., Lundin, K. E. A., Tveit, K. S., Lorentzen, M., Berset, I. P., et al. (2019) · Journal of Internal Medicine · doi:10.1111/joim.12880 · Cited by 123 · see citing works

Treatment of ulcerative colitis with adalimumab or infliximab: long‐term follow‐up of a single‐centre cohort

Gies, N., Kroeker, K. I., Wong, K., & Fedorak, R. N. (2010) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2010.04380.x · Cited by 103 · see citing works

Short and long‐term effectiveness and safety of vedolizumab in inflammatory bowel disease: results from the ENEIDA registry

Chaparro, M., Garre, A., Ricart, E., Iborra, M., Mesonero, F., Vera, I., Riestra, S., García-Sánchez, V., Castro, M. L. D., Martín‐Cardona, A., et al. (2018) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.14930 · Cited by 103 · see citing works

Long-Term Safety of Adalimumab in 29,967 Adult Patients From Global Clinical Trials Across Multiple Indications: An Updated Analysis

Burmester, G. R., Gordon, K. B., Rosenbaum, J. T., Arikan, D., Lau, W., Li, P., Faccin, F. J., & Panaccione, R. (2019) · Advances in Therapy · doi:10.1007/s12325-019-01145-8 · Cited by 94 · see citing works

Positioning Therapies in Ulcerative Colitis

Danese, S., Fiorino, G., & Peyrin‐Biroulet, L. (2020) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2020.01.017 · Cited by 83 · see citing works

Incidence of Arthritis/Arthralgia in Inflammatory Bowel Disease with Long-term Vedolizumab Treatment: Post Hoc Analyses of the GEMINI Trials

Feagan, B. G., Sandborn, W. J., Colombel, J., Byrne, S. O., Khalid, J. M., Kempf, C., Geransar, P., Bhayat, F., & Rubin, D. T. (2018) · Journal of Crohn s and Colitis · doi:10.1093/ecco-jcc/jjy125 · Cited by 81 · see citing works

Clinical Outcomes of Golimumab as First, Second or Third Anti-TNF Agent in Patients with Moderate-to-Severe Ulcerative Colitis

Taxonera, C., Rodríguez, C., Bertoletti, F., Menchen, L. A., Arribas, J., Sierra, M., Arias, L., Martínez-Montiel, P., Juan, A. J., Iglesias, E. L., et al. (2017) · Inflammatory Bowel Diseases · doi:10.1097/mib.0000000000001144 · Cited by 79 · see citing works

Anti-tumour necrosis factor-α therapy and recurrent or new primary cancers in patients with inflammatory bowel disease, rheumatoid arthritis, or psoriasis and previous cancer in Denmark: a nationwide, population-based cohort study

Waljee, A. K., Higgins, P., Jensen, C. B., Villumsen, M., Cohen‐Mekelburg, S., Wallace, B. I., Berinstein, J. A., Allin, K. H., & Jess, T. (2019) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(19)30362-0 · Cited by 73 · see citing works

Long‐term safety of adalimumab in clinical trials in adult patients with Crohn's disease or ulcerative colitis

Colombel, J., Sandborn, W. J., Reinisch, W., Peyrin‐Biroulet, L., Panaccione, R., Rutgeerts, P., Hanauer, S. B., Ghosh, S. K., Assche, G. V., Robinson, A. M., et al. (2017) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.14420 · Cited by 54 · see citing works

Safety of biological therapies in ulcerative colitis: An umbrella review of meta-analyses

Bonovas, S., Pantavou, K. G., Evripidou, D., Bastiampillai, A. J., Nikolopoulos, G. K., Peyrin‐Biroulet, L., & Danese, S. (2018) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2018.05.005 · Cited by 53 · see citing works

Vedolizumab use is not associated with increased malignancy incidence: GEMINI LTS study results and post‐marketing data

Card, T. R., Ungaro, R. C., Bhayat, F., Blake, A., Hantsbarger, G. L., & Travis, S. P. L. (2019) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.15538 · Cited by 53 · see citing works

Comparative of the Effectiveness and Safety of Biological Agents, Tofacitinib, and Fecal Microbiota Transplantation in Ulcerative Colitis: Systematic Review and Network Meta-Analysis

Zhou, H., Guo, B., Lufumpa, E., Li, X., Chen, L., Meng, X. L., & Li, B. (2020) · Immunological Investigations · doi:10.1080/08820139.2020.1714650 · Cited by 45 · see citing works

A 3‐year prospective study of a multidisciplinary early proactive therapeutic drug monitoring programme of infliximab treatments in inflammatory bowel disease

Sánchez‐Hernandez, J. G., Rebollo, N., Martín‐Suárez, A., Calvo, M. V. M., & Muñoz, F. (2020) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14229 · Cited by 42 · see citing works

Maintenance of Efficacy and Continuing Safety of Golimumab for Active Ulcerative Colitis: PURSUIT-SC Maintenance Study Extension Through 1 Year

Gibson, P. R., Feagan, B. G., Sandborn, W. J., Marano, C. W., Strauss, R. S., Johanns, J., Padgett, L., Collins, J. F., Tarabar, D. K., Hebzda, Z., et al. (2016) · Clinical and Translational Gastroenterology · doi:10.1038/ctg.2016.24 · Cited by 41 · see citing works

Efficacy and safety of biologic agents and tofacitinib in moderate‐to‐severe ulcerative colitis: A systematic overview of meta‐analyses

Pantavou, K. G., Yiallourou, A., Piovani, D., Evripidou, D., Danese, S., Peyrin‐Biroulet, L., Bonovas, S., & Nikolopoulos, G. K. (2019) · United European Gastroenterology Journal · doi:10.1177/2050640619883566 · Cited by 37 · see citing works

Long-Term Benefit of Golimumab for Patients with Moderately to Severely Active Ulcerative Colitis: Results from the PURSUIT-Maintenance Extension

Reinisch, W., Gibson, P. R., Sandborn, W. J., Feagan, B. G., Strauss, R. S., Johanns, J., Padgett, L., Adedokun, O. J., Colombel, J., Collins, J. F., et al. (2018) · Journal of Crohn s and Colitis · doi:10.1093/ecco-jcc/jjy079 · Cited by 35 · see citing works

A Simplified Algorithm for the Management of Hepatitis C Infection.

Dieterich, D. T. (2019) · PubMed Central · Cited by 35 · see citing works

Biosimilars of adalimumab: the upcoming challenge in IBD

Fiorino, G., Gilardi, D., Correale, C., Furfaro, F., Roda, G., Loy, L., ARGOLLO, M. C., Allocca, M., Peyrin‐Biroulet, L., & Danese, S. (2019) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2019.1564033 · Cited by 30 · see citing works

Long‐term efficacy and safety of CT‐P13, a biosimilar of infliximab, in patients with inflammatory bowel disease: A retrospective multicenter study

Kim, N. H., Lee, J. H., Hong, S. N., Yoon, H., Kang, H. W., Lee, S., Im, J. P., Cha, J. M., Eun, C. S., Kim, J. W., et al. (2019) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.14645 · Cited by 29 · see citing works

Respiratory Tract Infections in Patients With Inflammatory Bowel Disease: Safety Analyses From Vedolizumab Clinical Trials

Feagan, B. G., Bhayat, F., Khalid, J. M., Blake, A., & Travis, S. P. L. (2018) · Journal of Crohn s and Colitis · doi:10.1093/ecco-jcc/jjy047 · Cited by 27 · see citing works

Effectiveness and safety of adalimumab to treat outpatient ulcerative colitis

Tursi, A., Elisei, W., Faggiani, R., Allegretta, L., Valle, N. D., Forti, G., Franceschi, M., Ferronato, A., Gallina, S., Larussa, T., et al. (2018) · Medicine · doi:10.1097/md.0000000000011897 · Cited by 24 · see citing works

Safety Profile of Biologic Drugs in the Therapy of Ulcerative Colitis: A Systematic Review and Network Meta‐Analysis

Moćko, P., Kawalec, P., & Pilc, A. (2016) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1785 · Cited by 23 · see citing works

Long-term follow up after switching from original infliximab to an infliximab biosimilar: real-world data

Veloz, M. F. G., Jiménez, M. B., Delgado, T. V., Laria, L. C., Pérez, B. M., Amarillo, R. P., Bohórquez, V. M., Álvarez, Á. C., Vilches‐Arenas, Á., & Argüelles‐Arias, F. (2019) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756284819858052 · Cited by 18 · see citing works

Five-year Safety Data From OPUS, a European Observational Safety Registry for Adults With Ulcerative Colitis Treated With Originator Infliximab [Remicade®] or Conventional Therapy

Panés, J., Lindsay, J. O., Teich, N., Lindgren, S. C., Colombel, J., Cornillie, F. J., Flynn, H. A., Huyck, S. B., Stryszak, P., Yao, R., et al. (2019) · Journal of Crohn s and Colitis · doi:10.1093/ecco-jcc/jjz048 · Cited by 14 · see citing works

P473 Long-term follow-up of switching from original adalimumab to adalimumab biosimilar: real-world data in IBD

Suarez, C. P., Webb, K., Persad, N., Sercombe, J., Tyler, E. D., & Klimova, K. (2020) · Journal of Crohn s and Colitis · doi:10.1093/ecco-jcc/jjz203.602 · Cited by 4 · see citing works

Novel Targets For Therapeutic Intervention in Inflammatory Bowel Disease. What is the Best Way to Assess the Safety Profile of a Drug?

Yzet, C., Tse, S., Kayal, M., Hirten, R. P., & Colombel, J. (2019) · Current Pharmaceutical Design · doi:10.2174/1381612825666190308102021 · Cited by 3 · see citing works

P448 Dose adjustment in patients with moderate-to-severe ulcerative colitis: results from the UNIFI maintenance study long-term extension

Danese, S., Panaccione, R., Peyrin‐Biroulet, L., Marano, C. W., O’Brien, C., Zhang, H., Zhou, Y., Johanns, J., Scherl, E., Leong, R. W. L., et al. (2020) · Journal of Crohn s and Colitis · doi:10.1093/ecco-jcc/jjz203.577 · Cited by 3 · see citing works

P565 Efficacy and safety of long-term treatment with ustekinumab in moderate–severe ulcerative colitis patients with delayed response to ustekinumab induction: Results from UNIFI 2-year long-term extension

Sands, B. E., Abreu, M. T., Leong, R. W. L., Marano, C. W., O’Brien, C., Zhang, H., Zhou, Y., Johanns, J., Rowbotham, D. S., Hisamatsu, T., et al. (2020) · Journal of Crohn s and Colitis · doi:10.1093/ecco-jcc/jjz203.693 · Cited by 2 · see citing works

Tu1885 EFFICACY OF USTEKINUMAB FOR ULCERATIVE COLITIS IN BIOLOGIC NAÏVE, BIOLOGIC NON-FAILURE, AND BIOLOGIC FAILURE POPULATIONS THROUGH 2 YEARS: UNIFI LONG-TERM EXTENSION

Sands, B. E., Sandborn, W. J., Panaccione, R., O’Brien, C. D., Zhang, H., Johanns, J., Zhou, Y., Peyrin‐Biroulet, L., Scherl, E., Leong, R. W. L., et al. (2020) · Gastroenterology · doi:10.1016/s0016-5085(20)33672-6 · Cited by 2 · see citing works

DOP12 Efficacy of ustekinumab for ulcerative colitis through 2 years: Results of the UNIFI maintenance study and long-term extension

Panaccione, R., Sandborn, W. J., Sands, B. E., Marano, C. W., O’Brien, C. D., Zhang, H., Johanns, J. R., Zhou, Y., Peyrin‐Biroulet, L., Hisamatsu, T., et al. (2020) · Journal of Crohn s and Colitis · doi:10.1093/ecco-jcc/jjz203.051 · Cited by 1 · see citing works

Emerging issues in probiotic safety: 2023 perspectives

Merenstein, D., Pot, B., Leyer, G., Ouwehand, A. C., Preidis, G. A., Elkins, C. A., Hill, C., Lewis, Z. T., Shane, A. L., Zmora, N., et al. (2023) · Gut Microbes · doi:10.1080/19490976.2023.2185034 · Cited by 481 · see citing works

International consensus on the prevention of venous and arterial thrombotic events in patients with inflammatory bowel disease

Olivera, P. A., Zuily, S., Kotze, P. G., Regnault, V., Awadhi, S. A., Bossuyt, P. J., Gearry, R. B., Ghosh, S. K., Kobayashi, T., Lacolley, P. J., et al. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00492-8 · Cited by 154 · see citing works

Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies

Rubin, D. T., Allegretti, J. R., Panés, J., Shipitofsky, N. L., Yarandi, S., Huang, K. G., Germinaro, M., Wilson, R., Zhang, H., Johanns, J. R., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(24)01927-5 · Cited by 118 · see citing works

Qingre Xingyu recipe exerts inhibiting effects on ulcerative colitis development by inhibiting TNFα/NLRP3/Caspase-1/IL-1β pathway and macrophage M1 polarization

Ning, L., Ye, N., Bai, Y., Miao, Z., Cao, T., Lu, W., Xu, D., Tan, C., Xu, Y., & Yan, J. (2023) · Cell Death Discovery · doi:10.1038/s41420-023-01361-w · Cited by 19 · see citing works

The oft-overlooked cardiovascular complications of inflammatory bowel disease

Massironi, S., Mulinacci, G., Gallo, C., Viganò, C., Fichera, M., Villatore, A., Peretto, G., & Danese, S. (2023) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2023.2174971 · Cited by 17 · see citing works

Translational characterization of immune pathways in inflammatory bowel disease: insights for targeted treatments

Nicolò, S., Faggiani, I., Errico, C., D’Amico, F., Parigi, T. L., Danese, S., & Ungaro, F. (2024) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2024.2400300 · Cited by 12 · see citing works

Bupi Yichang Pill alleviates dextran sulfate sodium-induced ulcerative colitis in mice by regulating the homeostasis of follicular helper T cells

Zhong, Y., Xiao, Q., Li, S., Chen, L., Long, J., Fang, W., Yu, F., Huang, J., Zhao, H., & Liu, D. (2022) · Phytomedicine · doi:10.1016/j.phymed.2022.154091 · Cited by 12 · see citing works

Sishen pills inhibit inflammatory dendritic cell differentiation via miR-505–3p mediated E-cadherin downregulation in ulcerative colitis

Huang, J., Zhong, Y., Cheng, N., Zhang, Z., Huang, L., Song, L., Cheng, S., Zhao, H., & Liu, D. (2024) · Phytomedicine · doi:10.1016/j.phymed.2024.156035 · Cited by 10 · see citing works

The use of ileal pouch–anal anastomosis in patients with ulcerative colitis from 2009 to 2018

Kröner, P. T., Merchea, A., Colibaseanu, D., Picco, M. F., Farraye, F. A., & Stocchi, L. (2021) · Colorectal Disease · doi:10.1111/codi.15985 · Cited by 10 · see citing works

Comparative efficacy of pharmacologic interventions in ulcerative colitis: a network meta analysis

Khan, A. U., Ali, M., & Wahab, M. A. (2025) · Inflammopharmacology · doi:10.1007/s10787-025-01723-z · Cited by 7 · see citing works

Guselkumab in East Asians With Moderate‐to‐Severe Ulcerative Colitis: Subgroup Analysis of the QUASAR Induction and Maintenance Studies

Chen, B., Ye, B. D., Cao, Q., Hirai, F., Saruta, M., Chen, M., Pelak, S., Shipitofsky, N. L., Ye, M., Herr, K. J., et al. (2025) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.17036 · Cited by 7 · see citing works

Spanish Working Group in Crohn’s Disease and Ulcerative Colitis (GETECCU) position paper on cardiovascular disease in patients with inflammatory bowel disease

Marín‐Jiménez, I., Carpio, D., Hernández, V., Muñoz, F., Zatarain‐Nicolás, E., Zabana, Y., Mañosa, M., Rodríguez‐Moranta, F., Acosta, M. B., & Casbas, A. G. (2025) · Gastroenterología y Hepatología (English Edition) · doi:10.1016/j.gastre.2025.502314 · Cited by 6 · see citing works

Treat-to-Target and Regular Surveillance of Inflammatory Bowel Disease Are Associated with Low Incidence and Early-Stage Detection of Malignancies: A Retrospective Cohort Study

Parigi, T. L., Allocca, M., Furfaro, F., D’Amico, F., Zilli, A., Buono, A. D., Gabbiadini, R., Bonovas, S., Armuzzi, A., Danese, S., et al. (2023) · Cancers · doi:10.3390/cancers15245754 · Cited by 5 · see citing works

CLINICAL AND ECONOMIC ANALYSIS OF GENETICALLY ENGINEERED BIOLOGICS CONSUMPTION BY PATIENTS WITH COVID-19

Petrov, V. I., Ryazanova, A. Y., Ponomareva, A. V., Shatalova, O. V., & Levina, Y. V. (2022) · Pharmacy & Pharmacology · doi:10.19163/2307-9266-2022-10-2-198-206 · Cited by 5 · see citing works

Could small molecules be used in combination with biologics for inflammatory bowel disease?

D’Amico, F., Danese, S., & Fiorino, G. (2022) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2022.2104713 · Cited by 5 · see citing works

Peimine Alleviates DSS-Induced Colitis by Modulating Gut Microbiota and Attenuating Inflammation and Oxidative Stress

Guan, X., Han, D., Sha, H., Yao, M., Zhang, J., Zhang, G., Wu, Y., Su, D., & Yang, Q. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262211203 · Cited by 4 · see citing works

Documento de posicionamiento del Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU) sobre la enfermedad cardiovascular en los pacientes con enfermedad inflamatoria intestinal

Marín‐Jiménez, I., Carpio, D., Hernández, V., Muñoz, F., Zatarain‐Nicolás, E., Zabana, Y., Mañosa, M., Rodríguez‐Moranta, F., Acosta, M. B., & Gutiérrez, A. (2024) · Gastroenterología y Hepatología · doi:10.1016/j.gastrohep.2024.502314 · Cited by 6 · see citing works

Pulmonary Manifestations of IBD: Case Report and Review of the Literature

Herling, A., Perluk, T. M., Freund, O., Maharshak, N., & Cohen, N. A. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13185401 · Cited by 4 · see citing works

Long-Term Safety of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis: An Integrated 2-Year Safety Analysis

Lee, S., Ehrlich, A. C., Pellanda, P., Kaiser, C. J., Todd, K., Moses, R., & Walsh, A. J. (2025) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000003407 · Cited by 3 · see citing works

Alleviating ulcerative colitis via rectal administration: Enhancing the therapeutic effects of silk sericin-proanthocyanidins nanoparticles with a Poloxamer thermosensitive in situ gel

Zhang, J., Wang, C., Wu, X., & Lin, Y. (2025) · International Journal of Pharmaceutics X · doi:10.1016/j.ijpx.2025.100337 · Cited by 1 · see citing works

Ustekinumab versus vedolizumab and ustekinumab versus tumor necrosis factor alpha agent infectious adverse effects in patients with ulcerative colitis, a real-world data study

Almasri, H., Ismail, A. S., Khataniar, H., Butt, M. A., Karna, R., Bassett, J. T., & Moutsoglou, D. (2025) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2025.2564333 · Cited by 1 · see citing works

Comparative efficacy of pharmacological interventions in ulcerative colitis: A Network Meta AnalysisPreprint

Khan, A. U., Ali, M., & Wahab, M. A. (2025) · Research Square · doi:10.21203/rs.3.rs-6255469/v1 · Cited by 1 · see citing works

Surgical Management of the Complex Crohn’s and Ulcerative Colitis Patient: When to Redo a Pouch

Lynn, P. B., & Schwartzberg, D. M. (2021) · Clinical gastroenterology · doi:10.1007/978-3-030-81780-0_13

Predicting the Mechanism of Indirubin in the Treatment of Chronic Ulcerative Colitis Based on Public Database Analysis

Yang, T., Zhang, Y., Li, S., Sun, J., Wang, Y., & Deng, S. (2024) · IEEE International Conference on Bioinformatics and Biomedicine (BIBM) · doi:10.1109/bibm62325.2024.10821820

Identification and Verification of B4GALNT2 as an Epigenetic Marker in Ulcerative Colitis

Zhu, Y. Z., Zhou, Y. M., Jiang, H., Chen, Z., Lu, B., & Wu, J. (2025) · Digestion · doi:10.1159/000545944

Ulcerative colitis presenting with recurrent alternating bowel habits and rectal bleeding in a young female: a case report

Elhardalo, S. A., & Abuhzaima, E. A. (2025) · International Journal of Research in Medical Sciences · doi:10.18203/2320-6012.ijrms20252182

Lysosomal autophagy in the treatment of inflammatory bowel disease

Retnakumar, S. V. (2022) · theses.fr (ABES) · doi:10.70675/addbfec8zdb85z4eddz9c05zb59b895dc6c0

When Does Maintenance Efficacy End and Withdrawal Relapse Begin? Interpreting the QUASAR East Asian Subgroup Data

Huan, D. E. N. G., & Peng, Y. (2026) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.70418

A Box–Behnken-Optimized Phytosomal Strategy for Diosgenin: Enhancing Oral Delivery and Antipsoriatic Efficacy in a Preclinical Model

Kuppusamy, S., Gandhi, D. R., Epsiba, A., & SOWMYA, C. (2026) · ACS Omega · doi:10.1021/acsomega.5c13594

Safety of biological therapies in ulcerative colitis: An umbrella review of meta-analyses

Bonovas, S., Pantavou, K. G., Evripidou, D., Bastiampillai, A. J., Nikolopoulos, G. K., Peyrin‐Biroulet, L., & Danese, S. (2018) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2018.05.005 · Cited by 53 · see citing works

Safety Profile of Biologic Drugs in the Therapy of Ulcerative Colitis: A Systematic Review and Network Meta‐Analysis

Moćko, P., Kawalec, P., & Pilc, A. (2016) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1785 · Cited by 23 · see citing works

Additional file 1 of Network meta-analysis on efficacy and safety of different biologics for ulcerative colitis

Chu, X., Biao, Y., Liu, C., Zhang, Y., Liu, C., Ma, J.-Z., Guo, Y., & Gu, Y. (2023) · Figshare · doi:10.6084/m9.figshare.24264638

S1558 Long-Term Outcomes of Biologics in Ulcerative Colitis: A Network Meta-Analysis

Hassan, A., Mostafa, A., Elsenary, S., Elsayed, A., Mohamed, M., Ahmed, K., Kasem, N., Bekhit, N., Sayed, Z., & Elsayed, M. M. (2025) · The American Journal of Gastroenterology · doi:10.14309/01.ajg.0001133692.51566.d3

The Efficacy of Currently Licensed Biologics for Treatment of Ulcerative Colitis: A Literature Review

Awan, H., Fatima, U., Eaw, R., Knox, N., & Alrubaiy, L. (2023) · Cureus · doi:10.7759/cureus.37609 · Cited by 12 · see citing works